Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1292

—

cced3853-680d-5c92-8ee8-2d065311372e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.389
  • NOTCH_SIGNALING+0.381
  • HEDGEHOG_SIGNALING+0.283
  • E2F_TARGETS+0.263
  • G2M_CHECKPOINT+0.238
  • PANCREAS_BETA_CELLS+0.218
  • APICAL_SURFACE+0.187
  • COAGULATION+0.182
  • MITOTIC_SPINDLE+0.167
  • IL2_STAT5_SIGNALING+0.146

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.361
  • MTORC1_SIGNALING-0.311
  • ANDROGEN_RESPONSE-0.256
  • PROTEIN_SECRETION-0.254
  • UNFOLDED_PROTEIN_RESPONSE-0.237
  • MYC_TARGETS_V1-0.170
  • FATTY_ACID_METABOLISM-0.153
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.150
  • MYC_TARGETS_V2-0.145
  • GLYCOLYSIS-0.133

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG255
mng-umap@100
——0.762
2s_150324_1b
medullo-epn-umap@date-based
EPNSupratentorial EPN0.674
3R402
bladder-landscape@3
——0.658
420030032.TNBC
breast-umap@18
—D0.655
5MNG788
mng-umap@100
——0.654
6BS_M15PW2N0
medullo-epn-umap@date-based
MedMedulloblastoma0.653
7MDT-AP-0404
medullo-epn-umap@date-based
MedMedulloblastoma0.644
8SRR5088867
melanoma-umap@29
——0.642
9TCGA-56-8625-01A-11R-2403-07
lung-landscapes@6
—cohortSQ10.639
10BS_ZVWE73JZ
brain-umap@2
high-grade glioma—0.638

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.389Idelalisib— uncovered
NOTCH_SIGNALING0.381Inavolisib— uncovered
HEDGEHOG_SIGNALING0.283Inavolisib— uncovered
E2F_TARGETS0.263Inavolisib— uncovered
G2M_CHECKPOINT0.238Inavolisib— uncovered
PANCREAS_BETA_CELLS0.218Cobimetinib— uncovered
APICAL_SURFACE0.187Temsirolimus— uncovered
COAGULATION0.182Binimetinib— uncovered
MITOTIC_SPINDLE0.167Inavolisib— uncovered
IL2_STAT5_SIGNALING0.146Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.127Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.118Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.115Inavolisib— uncovered
APOPTOSIS0.112Idelalisib— uncovered
COMPLEMENT0.102Inavolisib— uncovered
MYOGENESIS0.088Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.074Inavolisib— uncovered
BILE_ACID_METABOLISM0.070Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.017Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.017Inavolisib— uncovered